Top-line Final Data from Cantrixil Phase I Study Confirms Prior Positive Efficacy and Safety Signals
[ad_1] SYDNEY, Dec. 9, 2020 /PRNewswire/ — Kazia Therapeutics Limited (ASX: KZA;NASDAQ: KZIA), an Australian oncology-focused biotechnology company, is pleased to share top-line final data from its phase I study of Cantrixil (TRX-E-002-1) in patients […]
